Skip to main content
Premium Trial:

Request an Annual Quote

Pacific Edge Diagnostics Receives Medicare Coverage for Bladder Cancer Test

NEW YORK – Cancer diagnostic company Pacific Edge Diagnostics announced Monday that its Cxbladder test is covered under Medicare Administrative Contractor Novitas' general local coverage decision for oncology biomarkers.

Novitas notified the firm of its coverage under the LCD, which covers a variety of oncology biomarkers used for diagnosis, classification, monitoring, surveillance, and prognosis. Biomarkers are covered under the LCD if they have proven clinical utility or validity; if there is uptake of specific testing into patient management; and if providers can demonstrate that use of the biomarkers will be used to help manage or treat the patient. For combination panels with multiple biomarkers, peer-reviewed full manuscript evidence is required.

New Zealand-based Pacific Edge Diagnostics' Cxbladder test is a urine-based assay for the diagnosis and management of bladder cancer. In the US, National Comprehensive Cancer Network guidelines have recognized it as an appropriate diagnostic test for the monitoring for recurrence of bladder cancer, the firm said in a statement. 

The test can be used for patients presenting with hematuria or for patients already diagnosed with bladder cancer under surveillance for recurrence. Cxbladder is covered for use on or after July 1.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.